Lonza has made a significant investment to expand its particle engineering and drug product capabilities at its Bend, OR site. New suites for the development and clinical manufacture of drug product intermediates and drug products using spray-drying, hot-melt extrusion and melt-spray-congeal processing will be completed by May 2022. The first suite will expand early-phase spray-drying, tableting and encapsulation capability and is expected to be on-line by December 2020. The new cGMP suites ...